Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.66 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.66 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 4/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | ITK | Q08881 | 2/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720709 | 0.97 | BTK (0.70) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL25075259 | 0.96 | BTK (0.65) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL25075054 | 0.96 | BTK (0.69) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL25075343 | 0.95 | BTK (0.64) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL24196555 | 0.94 | BTK (0.67) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL22720876 | 0.93 | BTK (0.65) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL24196915 | 0.93 | BTK (0.65) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL25075059 | 0.93 | BTK (0.67) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL30144790 | 0.93 | BTK (0.67) | BTKNUDT14NUDT5LCKLYN | |
| SCHEMBL30144656 | 0.92 | BTK (0.64) | BTKNUDT14NUDT5LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | BTK 1/4885NUDT14 3254/4885NUDT5 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.